![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Heico
HEI
5
Nova Minerals
NVA
US OptionsDetailed Quotes
ESPR250516P2000
- 0.00
- 0.000.00%
15min DelayClose May 1 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV-103.25%PremiumMay 16, 2025Expiry Date1.02Intrinsic Value100Multiplier14DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.76Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Esperion Therapeutics Stock Discussion
Sign in to post a comment
🚀 2 Biotech Stocks With Explosive Upside Potential: One Targeting a Mega Squeeze, the Other Tackling a $100B Market
While big pharma grabs headlines, two lesser-known biotech companies — Lexaria Bioscience (LEXX) and Esperion Therapeutics (ESPR) — are quietly positioning themselves for dramatic upside. One is addressing the biggest delivery problem in a $100B+ drug market, the other is potentially on the verge of...
While big pharma grabs headlines, two lesser-known biotech companies — Lexaria Bioscience (LEXX) and Esperion Therapeutics (ESPR) — are quietly positioning themselves for dramatic upside. One is addressing the biggest delivery problem in a $100B+ drug market, the other is potentially on the verge of...
11
1
$Esperion Therapeutics (ESPR.US)$Esperion Therapeutics (NASDAQ: ESPR): The Biotech Sleeper Poised for a Mega Short Squeeze
Esperion Therapeutics (NASDAQ: ESPR) is setting up as one of the most asymmetric and explosive trades in biotech. With two FDA-approved therapies, growing revenue, strategic partnerships, and a clear path to profitability, ESPR is firing on all cylinders.
And yet... the stock sti...
Esperion Therapeutics (NASDAQ: ESPR) is setting up as one of the most asymmetric and explosive trades in biotech. With two FDA-approved therapies, growing revenue, strategic partnerships, and a clear path to profitability, ESPR is firing on all cylinders.
And yet... the stock sti...
1
2
1
$Esperion Therapeutics (ESPR.US)$ to the moon?
4
$Esperion Therapeutics (ESPR.US)$
I will Bet Anyone If you BUY This STOCK Now You Will Make 150% Minimum By Years End, with 800% Upside
Please get your Cholesterol level checked every 6 months, it is the #1 cause of DEATH.
Why I’m Buying Esperion Therapeutics $Esperion Therapeutics (ESPR.US)$ in 2025: A Deeply Undervalued Biotech on the Edge of Profitability
Esperion Therapeutics (NASDA...
I will Bet Anyone If you BUY This STOCK Now You Will Make 150% Minimum By Years End, with 800% Upside
Please get your Cholesterol level checked every 6 months, it is the #1 cause of DEATH.
Why I’m Buying Esperion Therapeutics $Esperion Therapeutics (ESPR.US)$ in 2025: A Deeply Undervalued Biotech on the Edge of Profitability
Esperion Therapeutics (NASDA...
9
1
$Esperion Therapeutics (ESPR.US)$ the analyst ratings in the news section is comical. from like 2 to 16 dollars. lol. shouldn't be that much of a discrepancy. analysts are useless
2
2
$Esperion Therapeutics (ESPR.US)$ this js good mews but a way off anythibg tangible yet - we have to how the quarterly briefing they strongly outline nearterm revenue growth for the cholesterol lowerong drug
lifesciencerepo...
lifesciencerepo...
2
1
$Esperion Therapeutics (ESPR.US)$ Follow Linkedin posts by Esperion. $Novartis AG (NVS.US)$ is connected. I expect to hear a Big partnership or acquistion. The stock price is extremely undervalued.
1
3
$Esperion Therapeutics (ESPR.US)$ time to sell
Please get your Cholesterol level checked every 6 months, it is the #1 cause of DEATH.
Why I’m Buying Esperion Therapeutics $Esperion Therapeutics (ESPR.US)$ in 2025: A Deeply Undervalued Biotech on the Edge of Profitability
Esperion Therapeutics (NASDAQ: ESPR) looks like one of the most compelling—and misunderstood—opportunities in biotech. Despite having two FDA-approved drugs, expanding gl...
Why I’m Buying Esperion Therapeutics $Esperion Therapeutics (ESPR.US)$ in 2025: A Deeply Undervalued Biotech on the Edge of Profitability
Esperion Therapeutics (NASDAQ: ESPR) looks like one of the most compelling—and misunderstood—opportunities in biotech. Despite having two FDA-approved drugs, expanding gl...
+3
10
No comment yet
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. Do you think Buffett was scooping up stocks during the recent dip? 2. In the face of market changes, do you prefer to stick
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Tonyco : Interesting writeup.
I was long on ESPR for most of last year. Grabbed decent profits, but they ultimately dipped and crashed to pennies. Cut them loose after dilution(iirc).
Their valuation makes no sense to me, simply on sales alone.
I'm just sitting on alerts until they fly.